|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Walboomers JM, Jacobs MV, Manos MM, Bosch
FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ronco G, Dillner J, Elfström KM, Tunesi S,
Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi
P, et al: Efficacy of HPV-based screening for prevention of
invasive cervical cancer: Follow-up of four European randomised
controlled trials. Lancet. 383:524–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Castellsagué X: Natural history and
epidemiology of HPV infection and cervical cancer. Gynecol Oncol
110 (3 Suppl 2). S4–S7. 2008. View Article : Google Scholar
|
|
5
|
Alkatout I, Schubert M, Garbrecht N,
Weigel MT, Jonat W, Mundhenke C and Günther V: Vulvar cancer:
Epidemiology, clinical presentation, and management options. Int J
Womens Health. 7:305–313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DiSaia PJ, Creasman WT, Mannel RS,
McMeekin DS and Mutch DG: SPEC-clinical gynecologic oncology.
2017.Elsevier Health Sciences. PubMed/NCBI
|
|
8
|
Klattig J and Englert C: The Müllerian
duct: Recent insights into its development and regression. Sex Dev.
1:271–278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pappa KI, Rodolakis A, Christodoulou I,
Gazouli M, Markaki S, Antsaklis A and Anagnou NP: Comparative
assessment of lymph node micrometastasis in cervical, endometrial
and vulvar cancer: Insights on the real time qRT-PCR approach
versus immunohistochemistry, employing dual molecular markers.
Biomed Res Int. 2014:1876842014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res 41 (Database Issue).
D991–D995. 2013.
|
|
11
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pathan M, Keerthikumar S, Ang CS, Gangoda
L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim
A, et al: FunRich: An open access standalone functional enrichment
and interaction network analysis tool. Proteomics. 15:2597–2601.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res 45
(Database Issue). D362–D368. 2017. View Article : Google Scholar
|
|
14
|
Wang J, Duncan DT, Shi Z and Zhang B:
WEB-based GEne SeT analysis toolkit (WebGestalt): Update 2013.
Nucleic Acids Res 41 (Web Server Issue). W77–W83. 2013. View Article : Google Scholar
|
|
15
|
Hu Y, Pan Z, Hu Y, Zhang L and Wang J:
Network and pathway-based analyses of genes associated with
parkinson's disease. Mol Neurobiol. 54:4452–4465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franz M, Lopes CT, Huck G, Dong Y, Sumer O
and Bader GD: Cytoscape.js: A graph theory library for
visualisation and analysis. Bioinformatics. 32:309–311.
2016.PubMed/NCBI
|
|
17
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia P, Kao CF, Kuo PH and Zhao Z: A
comprehensive network and pathway analysis of candidate genes in
major depressive disorder. BMC Syst Biol. 5 (Suppl 3):S122011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nigg EA: Mitotic kinases as regulators of
cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li L, Qu YW and Li YP: Over-expression of
miR-1271 inhibits endometrial cancer cells proliferation and
induces cell apoptosis by targeting CDK1. Eur Rev Med Pharmacol
Sci. 21:2816–2822. 2017.PubMed/NCBI
|
|
21
|
Kang J, Sergio CM, Sutherland RL and
Musgrove EA: Targeting cyclin-dependent kinase 1 (CDK1) but not
CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast
cancer cells. BMC Cancer. 14:322014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xi Q, Huang M, Wang Y, Zhong J, Liu R, Xu
G, Jiang L, Wang J, Fang Z and Yang S: The expression of CDK1 is
associated with proliferation and can be a prognostic factor in
epithelial ovarian cancer. Tumour Biol. 36:4939–4948. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo Y, Wu Y, Peng Y, Liu X, Bie J and Li
S: Systematic analysis to identify a key role of CDK1 in mediating
gene interaction networks in cervical cancer development. Ir J Med
Sci. 185:231–239. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bidus MA, Risinger JI, Chandramouli GV,
Dainty LA, Litzi TJ, Berchuck A, Barrett JC and Maxwell GL:
Prediction of lymph node metastasis in patients with endometrioid
endometrial cancer using expression microarray. Clin Cancer Res.
12:83–88. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang W, Liu Y, Zhao N, Chen H, Qiao L,
Zhao W and Chen JJ: Role of Cdk1 in the p53-independent abrogation
of the postmitotic checkpoint by human papillomavirus E6. J Virol.
89:2553–2562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ruan JS, Zhou H, Yang L, Wang L, Jiang ZS
and Wang SM: CCNA2 facilitates epithelial-to-mesenchymal transition
via the integrin αvβ3 signaling in NSCLC. Int J Clin Exp Pathol.
10:8324–8333. 2017.
|
|
27
|
He Y, Liu J, Zhao Z and Zhao H:
Bioinformatics analysis of gene expression profiles of esophageal
squamous cell carcinoma. Dis Esophagus. 30:1–8. 2017. View Article : Google Scholar
|
|
28
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Zhang W, Li X, Li D, Zhang X, Yin
Y, Deng X and Sheng X: Prognostic factors and genes associated with
endometrial cancer based on gene expression profiling by
bioinformatics analysis. Arch Gynecol Obstet. 293:1287–1295. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC and
Lee HP: Identification of genes with differential expression in
chemoresistant epithelial ovarian cancer using high-density
oligonucleotide microarrays. Oncol Res. 18:47–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Catarino R, Matos A, Pinto D, Pereira D,
Craveiro R, Vasconcelos A, Lopes C and Medeiros R: Increased risk
of cervical cancer associated with cyclin D1 gene A870G
polymorphism. Cancer Genet Cytogenet. 160:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rolfe KJ, Crow JC, Benjamin E, Reid WM,
Maclean AB and Perrett CW: Cyclin D1 and retinoblastoma protein in
vulvar cancer and adjacent lesions. Int J Gynecol Cancer.
11:381–386. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lerma E, Esteller M, Herman JG and Prat J:
Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma,
vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol.
33:1120–1125. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moreno-Bueno G, Rodríguez-Perales S,
Sánchez-Estévez C, Marcos R, Hardisson D, Cigudosa JC and Palacios
J: Molecular alterations associated with cyclin d1 overexpression
in endometrial cancer. Int J Cancer. 110:194–200. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kurvinen K, Syrjänen K and Syrjänen S: p53
and bcl-2 proteins as prognostic markers in human
papillomavirus-associated cervical lesions. J Clin Oncol.
14:2120–2130. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kamaraddi S, Ashwini NU, Honnappa S and
Swarup A: Expression of bcl-2 marker in premalignant lesions of
cervical cancer. Int J Reprod Contrac Obstet Gynecol. 5:965–969.
2016. View Article : Google Scholar
|
|
37
|
Aletra C, Ravazoula P, Scopa C, Kounelis
S, Sotiropoulou G, Kourounis G, Ladopoulos I and Bonikos D:
Expression of bcl-2 and bax in cervical intraepithelial neoplasia
and invasive squamous cell carcinoma of the uterine cervix. Eur J
Gynaecol Oncol. 21:494–498. 2000.PubMed/NCBI
|
|
38
|
Iyer P, Radhakrishnan V, Vyas R and
Trivedi S: Study on the effect of chemo-radiation on the serum
levels of IGF-I in patients with cancer cervix stage IIIB. Ind J
Gynecol Oncol. 15:342017. View Article : Google Scholar
|
|
39
|
Peyrat JP, Bonneterre J, Hecquet B, Vennin
P, Louchez MM, Fournier C, Lefebvre J and Demaille A: Plasma
insulin-like growth factor-1 (IGF-1) concentrations in human breast
cancer. Eur J Cancer 29A. 492–497. 1993. View Article : Google Scholar
|
|
40
|
Vanamala J, Reddivari L, Radhakrishnan S
and Tarver C: Resveratrol suppresses IGF-1 induced human colon
cancer cell proliferation and elevates apoptosis via suppression of
IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer.
10:2382010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liao Y, Lu W, Che Q, Yang T, Qiu H, Zhang
H, He X, Wang J, Qiu M, Zou Y, et al: SHARP1 suppresses
angiogenesis of endometrial cancer by decreasing hypoxia-inducible
factor-1α level. PLoS One. 9:e999072014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baeriswyl V and Christofori G: The
angiogenic switch in carcinogenesis. Semin Cancer Biol. 19:329–337.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen HX, Xu XX, Tan BZ, Zhang Z and Zhou
XD: MicroRNA-29b inhibits angiogenesis by targeting VEGFA through
the MAPK/ERK and PI3K/Akt signaling pathways in endometrial
carcinoma. Cell Physiol Biochem. 41:933–946. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hua F and Tian Y: CCL4 promotes the cell
proliferation, invasion and migration of endometrial carcinoma by
targeting the VEGF-A signal pathway. Int J Clin Exp Pathol.
10:11288–11299. 2017.
|
|
45
|
Itoh N: The Fgf families in humans, mice,
and zebrafish: Their evolutional processes and roles in
development, metabolism, and disease. Biol Pharm Bull.
30:1819–1825. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Presta M, Dell'Era P, Mitola S, Moroni E,
Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth
factor receptor system in angiogenesis. Cytokine Growth Factor Rev.
16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Folkman J and Klagsbrun M: Angiogenic
factors. Science. 235:442–447. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cheng YM, Chou CY, Hsu YC and Chen MJ:
Influence of HPV16 E6/7 on the expression of FGF2 and FGFR type B
in cervical carcinogenesis. Reprod Sci. 19:580–586. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng YM, Chou CY, Chang FM and Wing LYC:
Fibroblast growth factor receptor 1 (FGFR1) overexpression play a
possible role in cervical carcinogenesis: 0453. Int J Gynecol
Cancer. 728:2006.
|
|
50
|
Huang JK, Ma L, Song WH, Lu BY, Huang YB,
Dong HM, Ma XK, Zhu ZZ and Zhou R: LncRNA-MALAT1 promotes
angiogenesis of thyroid cancer by modulating tumor-associated
macrophage FGF2 protein secretion. J Cell Biochem. 118:4821–4830.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee PS and Secord AA: Targeting molecular
pathways in endometrial cancer: A focus on the FGFR pathway. Cancer
Treat Rev. 40:507–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fujimoto J, Hori M, Ichigo S and Tamaya T:
Expressions of the fibroblast growth factor family (FGF-1, −2 and
−4) mRNA in endometrial cancers. Tumour Biol. 17:226–233. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yung MM, Chan DW, Liu VW, Yao KM and Ngan
HY: Activation of AMPK inhibits cervical cancer cell growth through
AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 13:3272013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang Y, Goodfellow R, Li Y, Yang S,
Winters CJ, Thiel KW, Leslie KK and Yang B: NEDD4 ubiquitin ligase
is a putative oncogene in endometrial cancer that activates
IGF-1R/PI3K/Akt signaling. Gynecol Oncol. 139:127–133. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pavlidou A and Vlahos NF: Molecular
alterations of PI3K/Akt/mTOR pathway: A therapeutic target in
endometrial cancer. ScientificWorldJournal. 2014:7097362014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cheaib B, Auguste A and Leary A: The
PI3K/Akt/mTOR pathway in ovarian cancer: Therapeutic opportunities
and challenges. Chin J Cancer. 34:4–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Boras EA, Matou-nasri S, Kuprinski J,
Badimon L, Potempa LA and Slevin M: Abstract 181: Common angiogenic
signalling pathways induced by monomeric c-reactive protein and
FGF-2 through phosphatidylinositol 3-kinase. Stroke.
43:A1812012.
|
|
61
|
Liu Y, Liu H, Zou J, Zhang B and Yuan Z:
Dengue virus subgenomic RNA induces apoptosis through the
Bcl-2-mediated PI3k/Akt signaling pathway. Virology. 448:15–25.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Luna-López A, Triana-Martínez F,
López-Diazguerrero NE, Ventura-Gallegos JL, Gutiérrez-Ruiz MC,
Damián-Matsumura P, Zentella A, Gómez-Quiroz LE and Königsberg M:
Bcl-2 sustains hormetic response by inducing Nrf-2 nuclear
translocation in L929 mouse fibroblasts. Free Radic Biol Med.
49:1192–1204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gopinathan L, Tan SL, Padmakumar VC,
Coppola V, Tessarollo L and Kaldis P: Loss of Cdk2 and cyclin A2
impairs cell proliferation and tumorigenesis. Cancer Res.
74:3870–3879. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Suman S and Mishra A: Network analysis
revealed aurora kinase dysregulation in five gynecological types of
cancer. Oncol Lett. 15:1125–1132. 2018.PubMed/NCBI
|
